|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang H and Chen L: Tumor microenviroment
and hepatocellular carcinoma metastasis. J Gastroenterol Hepatol.
28:(Suppl 1). 43–48. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Iwatsuki M, Mimori K, Yokobori T, Ishi H,
Beppu T, Nakamori S, Baba H and Mori M: Epithelial-mesenchymal
transition in cancer development and its clinical significance.
Cancer Sci. 101:293–299. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yamada S, Okumura N, Wei L, Fuchs BC,
Fujii T, Sugimoto H, Nomoto S, Takeda S, Tanabe KK and Kodera Y:
Epithelial to mesenchymal transition is associated with shorter
disease-free survival in hepatocellular carcinoma. Ann Surg Oncol.
21:3882–3890. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hussain SP and Harris CC: Inflammation and
cancer: An ancient link with novel potentials. Int J Cancer.
121:2373–2380. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
López-Novoa JM and Nieto MA: Inflammation
and EMT: An alliance towards organ fibrosis and cancer progression.
EMBO Mol Med. 1:303–314. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rose-John S, Waetzig GH, Scheller J,
Grötzinger J and Seegert D: The IL-6/sIL-6R complex as a novel
target for therapeutic approaches. Expert Opin Ther Targets.
11:613–624. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Grivennikov SI and Karin M: Inflammatory
cytokines in cancer: Tumour necrosis factor and interleukin 6 take
the stage. Ann Rheum Dis. 70:(Suppl 1). i104–i108. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rokavec M, Wu W and Luo JL: IL6-mediated
suppression of miR-200c directs constitutive activation of
inflammatory signaling circuit driving transformation and
tumorigenesis. Mol Cell. 45:777–789. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Porta C, De Amici M, Quaglini S, Paglino
C, Tagliani F, Boncimino A, Moratti R and Corazza GR: Circulating
interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann
Oncol. 19:353–358. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shackel NA, McCaughan GW and Warner FJ:
Hepatocellular carcinoma development requires hepatic stem cells
with altered transforming growth factor and interleukin-6
signaling. Hepatology. 47:2134–2136. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wong VW, Yu J, Cheng AS, Wong GL, Chan HY,
Chu ES, Ng EK, Chan FK, Sung JJ and Chan HL: High serum
interleukin-6 level predicts future hepatocellular carcinoma
development in patients with chronic hepatitis B. Int J Cancer.
124:2766–2770. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu H, Pardoll D and Jove R: STATs in
cancer inflammation and immunity: A leading role for STAT3. Nat Rev
Cancer. 9:798–809. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Colomiere M, Ward AC, Riley C, Trenerry
MK, Cameron-Smith D, Findlay J, Ackland L and Ahmed N: Cross talk
of signals between EGFR and IL-6R through JAK2/STAT3 mediate
epithelial-mesenchymal transition in ovarian carcinomas. Br J
Cancer. 100:134–144. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen W, Gao Q, Han S, Pan F and Fan W: The
CCL2/CCR2 axis enhances IL-6-induced epithelial-mesenchymal
transition by cooperatively activating STAT3-Twist signaling.
Tumour Biol. 36:973–981. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cheng GZ, Zhang WZ, Sun M, Wang Q, Coppola
D, Mansour M, Xu LM, Costanzo C, Cheng JQ and Wang LH: Twist is
transcriptionally induced by activation of STAT3 and mediates STAT3
oncogenic function. J Biol Chem. 283:14665–14673. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ho YP, To KK, Au-Yeung SC, Wang X, Lin G
and Han X: Potential new antitumor agents from an innovative
combination of demethylcantharidin, a modified traditional Chinese
medicine, with a platinum moiety. J Med Chem. 44:2065–2068. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang GS: Medical uses of mylabris in
ancient China and recent studies. J Ethnopharmacol. 26:147–162.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen YN, Chen JC, Yin SC, Wang GS, Tsauer
W, Hsu SF and Hsu SL: Effector mechanisms of norcantharidin-induced
mitotic arrest and apoptosis in human hepatoma cells. Int J Cancer.
100:158–165. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fan YZ, Zhao ZM, Fu JY, Chen CQ and Sun W:
Norcantharidin inhibits growth of human gallbladder carcinoma
xenografted tumors in nude mice by inducing apoptosis and blocking
the cell cycle in vivo. Hepatobiliary Pancreat Dis Int. 9:414–422.
2010.PubMed/NCBI
|
|
23
|
Fan YZ, Fu JY, Zhao ZM and Chen CQ:
Inhibitory effect of norcantharidin on the growth of human
gallbladder carcinoma GBC-SD cells in vitro. Hepatobiliary Pancreat
Dis Int. 6:72–80. 2007.PubMed/NCBI
|
|
24
|
Kok SH, Cheng SJ, Hong CY, Lee JJ, Lin SK,
Kuo YS, Chiang CP and Kuo MY: Norcantharidin-induced apoptosis in
oral cancer cells is associated with an increase of proapoptotic to
antiapoptotic protein ratio. Cancer Lett. 217:43–52. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yu CC, Ko FY, Yu CS, Lin CC, Huang YP,
Yang JS, Lin JP and Chung JG: Norcantharidin triggers cell death
and DNA damage through S-phase arrest and ROS-modulated apoptotic
pathways in TSGH 8301 human urinary bladder carcinoma cells. Int J
Oncol. 41:1050–1060. 2012.PubMed/NCBI
|
|
26
|
Yang PY, Chen MF, Kao YH, Hu DN, Chang FR
and Wu YC: Norcantharidin induces apoptosis of breast cancer cells:
Involvement of activities of mitogen activated protein kinases and
signal transducers and activators of transcription. Toxicol In
Vitro. 25:699–707. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang Y, Liu Q, Liu K, Yagasaki K and
Zhang G: Suppression of growth of highly-metastatic human breast
cancer cells by norcantharidin and its mechanisms of action.
Cytotechnology. 59:2092009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen YJ, Kuo CD, Tsai YM, Yu CC, Wang GS
and Liao HF: Norcantharidin induces anoikis through Jun-N-terminal
kinase activation in CT26 colorectal cancer cells. Anticancer
Drugs. 19:55–64. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Luan J, Duan H, Liu Q, Yagasaki K and
Zhang G: Inhibitory effects of norcantharidin against human lung
cancer cell growth and migration. Cytotechnology. 62:349–355. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu Q, Duan H, Luan J, Yagasaki K and
Zhang G: Effects of theanine on growth of human lung cancer and
leukemia cells as well as migration and invasion of human lung
cancer cells. Cytotechnology. 59:211–217. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Blaskovich MA, Sun J, Cantor A, Turkson J,
Jove R and Sebti SM: Discovery of JSI-124 (cucurbitacin I), a
selective Janus kinase/signal transducer and activator of
transcription 3 signaling pathway inhibitor with potent antitumor
activity against human and murine cancer cells in mice. Cancer Res.
63:1270–1279. 2003.PubMed/NCBI
|
|
32
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nieto MA: The ins and outs of the
epithelial to mesenchymal transition in health and disease. Annu
Rev Cell Dev Biol. 27:347–376. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: At the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nieto MA and Cano A: The
epithelial-mesenchymal transition under control: Global programs to
regulate epithelial plasticity. Semin Cancer Biol. 22:361–368.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee TK, Poon RT, Yuen AP, Ling MT, Kwok
WK, Wang XH, Wong YC, Guan XY, Man K, Chau KL, et al: Twist
overexpression correlates with hepatocellular carcinoma metastasis
through induction of epithelial-mesenchymal transition. Clin Cancer
Res. 12:5369–5376. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lee TK, Man K, Poon RT, Lo CM, Yuen AP, Ng
IO, Ng KT, Leonard W and Fan ST: Signal transducers and activators
of transcription 5b activation enhances hepatocellular carcinoma
aggressiveness through induction of epithelial-mesenchymal
transition. Cancer Res. 66:9948–9956. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Giannelli G, Bergamini C, Fransvea E,
Sgarra C and Antonaci S: Laminin-5 with transforming growth
factor-beta1 induces epithelial to mesenchymal transition in
hepatocellular carcinoma. Gastroenterology. 129:1375–1383. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yadav A, Kumar B, Datta J, Teknos TN and
Kumar P: IL-6 promotes head and neck tumor metastasis by inducing
epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling
pathway. Mol Cancer Res. 9:1658–1667. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sullivan NJ, Sasser AK, Axel AE, Vesuna F,
Raman V, Ramirez N, Oberyszyn TM and Hall BM: Interleukin-6 induces
an epithelial-mesenchymal transition phenotype in human breast
cancer cells. Oncogene. 28:2940–2947. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lederle W, Depner S, Schnur S, Obermueller
E, Catone N, Just A, Fusenig NE and Mueller MM: IL-6 promotes
malignant growth of skin SCCs by regulating a network of autocrine
and paracrine cytokines. Int J Cancer. 128:2803–2814. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li Y, Tian B, Yang J, Zhao L, Wu X, Ye SL,
Liu YK and Tang ZY: Stepwise metastatic human hepatocellular
carcinoma cell model system with multiple metastatic potentials
established through consecutive in vivo selection and studies on
metastatic characteristics. J Cancer Res Clin Oncol. 130:460–468.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yao J, Liang L, Huang S, Ding J, Tan N,
Zhao Y, Yan M, Ge C, Zhang Z, Chen T, et al: MicroRNA-30d promotes
tumor invasion and metastasis by targeting Galphai2 in
hepatocellular carcinoma. Hepatology. 51:846–856. 2010.PubMed/NCBI
|
|
45
|
Miao JW, Liu LJ and Huang J:
Interleukin-6-induced epithelial-mesenchymal transition through
signal transducer and activator of transcription 3 in human
cervical carcinoma. Int J Oncol. 45:165–176. 2014.PubMed/NCBI
|
|
46
|
Su Y, Li G, Zhang X, Gu J, Zhang C, Tian Z
and Zhang J: JSI-124 inhibits glioblastoma multiforme cell
proliferation through G(2)/M cell cycle arrest and apoptosis
augment. Cancer Biol Ther. 7:1243–1249. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu AN, Zhu ZH, Chang SJ and Hang XS:
Twist expression associated with the epithelial-mesenchymal
transition in gastric cancer. Mol Cell Biochem. 367:195–203. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sasaki K, Natsugoe S, Ishigami S,
Matsumoto M, Okumura H, Setoyama T, Uchikado Y, Kita Y, Tamotsu K,
Sakamoto A, et al: Significance of Twist expression and its
association with E-cadherin in esophageal squamous cell carcinoma.
J Exp Clin Cancer Res. 28:1582009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bromberg J and Wang TC: Inflammation and
cancer: IL-6 and STAT3 complete the link. Cancer Cell. 15:79–80.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Huang C, Yang G, Jiang T, Zhu G, Li H and
Qiu Z: The effects and mechanisms of blockage of STAT3 signaling
pathway on IL-6 inducing EMT in human pancreatic cancer cells in
vitro. Neoplasma. 58:396–405. 2011. View Article : Google Scholar : PubMed/NCBI
|
